Danaher Corporation

LSE:0R2B Stock Report

Market Cap: US$165.1b

Danaher Valuation

Is 0R2B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0R2B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0R2B ($230.37) is trading above our estimate of fair value ($210.62)

Significantly Below Fair Value: 0R2B is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0R2B?

Key metric: As 0R2B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0R2B. This is calculated by dividing 0R2B's market cap by their current earnings.
What is 0R2B's PE Ratio?
PE Ratio42x
EarningsUS$3.93b
Market CapUS$165.08b

Price to Earnings Ratio vs Peers

How does 0R2B's PE Ratio compare to its peers?

The above table shows the PE ratio for 0R2B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.9x
AZN AstraZeneca
30.8x18.2%UK£159.0b
GSK GSK
21.5x23.2%UK£53.9b
ERGO Ergomed
46.7x14.2%UK£701.1m
TMO Thermo Fisher Scientific
32.7x11.5%US$200.4b
0R2B Danaher
42x13.4%US$165.1b

Price-To-Earnings vs Peers: 0R2B is expensive based on its Price-To-Earnings Ratio (42x) compared to the peer average (28.3x).

Price to Earnings Ratio vs Industry

How does 0R2B's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0R2B 42.0xIndustry Avg. 37.4xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0R2B is expensive based on its Price-To-Earnings Ratio (42x) compared to the European Life Sciences industry average (37.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0R2B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0R2B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42x
Fair PE Ratio36.7x

Price-To-Earnings vs Fair Ratio: 0R2B is expensive based on its Price-To-Earnings Ratio (42x) compared to the estimated Fair Price-To-Earnings Ratio (36.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0R2B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$230.37
US$288.60
+25.3%
5.7%US$315.00US$255.00n/a25
Dec ’25US$239.69
US$290.13
+21.0%
5.7%US$315.00US$255.00n/a24
Nov ’25US$248.27
US$289.75
+16.7%
5.9%US$315.00US$255.00n/a24
Oct ’25US$274.17
US$289.35
+5.5%
7.1%US$333.00US$250.00n/a23
Sep ’25US$266.00
US$285.87
+7.5%
6.4%US$310.00US$250.00n/a22
Aug ’25US$280.07
US$286.15
+2.2%
6.5%US$310.00US$250.00n/a21
Jul ’25US$243.73
US$273.39
+12.2%
7.6%US$300.00US$220.00n/a23
Jun ’25US$254.00
US$272.78
+7.4%
7.5%US$300.00US$220.00n/a23
May ’25US$245.25
US$270.08
+10.1%
8.8%US$300.00US$208.00n/a24
Apr ’25US$250.36
US$262.17
+4.7%
9.1%US$300.00US$208.00n/a24
Mar ’25US$256.05
US$260.75
+1.8%
9.3%US$300.00US$208.00n/a24
Feb ’25US$243.42
US$260.33
+6.9%
9.3%US$300.00US$208.00n/a24
Jan ’25US$231.42
US$247.16
+6.8%
10.3%US$306.00US$205.00n/a25
Dec ’24US$222.80
US$241.52
+8.4%
10.3%US$306.00US$208.00US$239.6923
Nov ’24US$190.36
US$242.39
+27.3%
10.6%US$306.00US$208.00US$248.2723
Oct ’24US$248.81
US$283.58
+14.0%
5.4%US$306.00US$240.00US$274.1723
Sep ’24US$265.10
US$283.97
+7.1%
6.2%US$325.00US$240.00US$266.0024
Aug ’24US$255.00
US$285.04
+11.8%
6.8%US$328.00US$240.00US$280.0722
Jul ’24US$240.06
US$278.59
+16.1%
9.0%US$356.00US$250.00US$243.7322
Jun ’24US$233.59
US$279.50
+19.7%
8.8%US$356.00US$250.00US$254.0022
May ’24US$238.37
US$282.86
+18.7%
9.7%US$356.00US$242.00US$245.2521
Apr ’24US$251.64
US$302.35
+20.2%
8.2%US$365.00US$242.00US$250.3620
Mar ’24US$246.03
US$302.85
+23.1%
8.2%US$365.00US$242.00US$256.0520
Feb ’24US$265.39
US$302.85
+14.1%
8.2%US$365.00US$242.00US$243.4220
Jan ’24US$263.22
US$304.71
+15.8%
8.0%US$342.00US$242.00US$231.4221
Dec ’23US$275.02
US$305.63
+11.1%
8.2%US$342.00US$242.00US$222.8019

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 16:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/27
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Danaher Corporation is covered by 54 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Catherine Ramsey SchulteBaird
Ishan MajumdarBaptista Research